Connect with us

Business

Abercrombie sales growth slows again, but Hollister surges 19%

Published

on

Abercrombie sales growth slows again, but Hollister surges 19%


Abercrombie & Fitch sales growth slowed again in its fiscal second quarter as the apparel company struggles to top the surge it enjoyed last fiscal year.

During the quarter, sales at the namesake Abercrombie brand fell 5% while comparable sales dropped 11%. 

But the success of teen-focused Hollister brand helped to salvage the quarter. Overall, Abercrombie & Fitch sales climbed 7%, led by 19% growth at Hollister – the brand’s best-ever second-quarter net sales growth, the company said. Comparable sales across the business rose 3%, led by Hollister, which also saw comparable sales grow 19%.

Abercrombie narrowly beat Wall Street expectations on the top and bottom lines. The company also hiked its full-year revenue outlook and now expects sales to climb 5% to 7%, compared with previous guidance of 3% to 6% growth. Much of that range would top Wall Street expectations of 5.2% growth, according to LSEG.

Shares fell nearly 4% in premarket trading.

Here’s how the company did in its second fiscal quarter compared with what Wall Street was anticipating, based on a survey of analysts by LSEG:

  • Earnings per share: $2.32 adjusted vs. $2.30 expected
  • Revenue: $1.21 billion  vs. $1.20 billion expected

The company’s reported net income for the three-month period that ended August 2 was $141 million, or $2.91 per share, compared with $133 million, or $2.50 a share, a year earlier. Excluding the impact of a favorable litigation settlement, Abercrombie saw earnings of $2.32 per share.

Sales rose to $1.21 billion, up about 7% from $1.13 billion a year earlier. 

“We entered the second half of 2025 on offense,” CEO Fran Horowitz said in a news release. “We are increasing our full year net sales outlook, reflecting our strong positioning and growth trajectory, building on record 2024 results. Our team remains focused on delivering for our customers while investing to capitalize on the significant, long-term opportunities for our global brands.”

For its current quarter, Abercrombie’s also gave a better-than-expected sales outlook. It anticipates revenue will rise between 5% and 7%, beating expectations of 4.3% growth, according to LSEG.

Meanwhile, its profit outlook for the fiscal third quarter is weaker than expected. The company anticipates earnings per share will be between $2.05 and $2.25, far below expectations of $2.53, according to LSEG. 

For the full year, Abercrombie tightened its earnings outlook and now expects earnings per share to be between $10.00 and $10.50, about in line with expectations of $10.15, according to LSEG.

Abercrombie’s guidance incorporates about $90 million in net tariff costs – nearly double what it previously anticipated. When it announced fiscal first quarter earnings in May, Abercrombie said it was expecting a $70 million hit from tariffs that it could reduce to $50 million through mitigation.

At the time, President Donald Trump’s so-called reciprocal tariffs were held at 10% across most of the globe. But now Abercrombie faces higher duties on goods from Vietnam, Cambodia and India, key manufacturing regions for the company. 

At the time, the company said it wasn’t planning broad price increases as part of its mitigation efforts. It’s unclear if Abercrombie will change that stance now that tariffs have increased across Asia. 

Abercrombie & Fitch, once a forgotten mall brand, has been on a rocket ship of growth over the last few years. But the surge has started to slow at its namesake banner.

The company has turned to new categories, such as dresses, athleisure and bridal, to stimulate growth. It’s also working to expand internationally and lean on partnerships. 

On Monday, the company announced it would be the NFL’s first “official fashion partner” – a multiyear deal that will include personal styling for athletes, athlete-led campaigns and player-designed apparel. The partnership comes after Abercrombie launched an assortment of NFL licensed products in 2022, a category that has performed well for the company. 

It has teamed up with star players like Christian McCaffrey, Tee Higgins and CeeDee Lamb to advertise the partnership and designed limited-edition co-designed apparel that will be available for sale during the upcoming season. 

The partnership reflects the steps retailers are taking to ensure they can continue to grow sales and stay relevant with consumers at a time when shoppers are pulling back on nice-to-have items like new clothes and accessories. Competitors like Levi, American Eagle and Gap have teamed up with celebrities in recent marketing campaigns ahead of the back to school and fall shopping seasons.

Internationally, Abercrombie’s efforts to expand are paying off in some parts of the world. During the quarter, sales in its Asia Pacific region grew 12%, while comparable sales climbed 3%. That was offset by a slowdown in Europe, the Middle East and Africa, where sales slid 1% and comparable sales were down 5%. 



Source link

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Business

Indigo Shares Decline Over 4% On Promoter Offloading Stake

Published

on

Indigo Shares Decline Over 4% On Promoter Offloading Stake


Mumbai: The shares of InterGlobe Aviation, the parent company of IndiGo Airlines, tanked over 4 per cent in the early trading on Thursday on news of promoter Rakesh Gangwal’s family selling stocks worth Rs 7,085 crore through a block deal.  

At around 11:38 am, the shares were trading at Rs 5,789.0, down 4.31 per cent or Rs 261.

The promoter family is likely to sell 1.2 lakh shares, worth Rs 7,085 crore, at an average price of Rs 5,830 per share.

Add Zee News as a Preferred Source


(Also Read: Key Financial Rules Changing From September 2025)

 

According to earlier media reports, the Gangwal family plans to sell up to 3.1 per cent of InterGlobe Aviation through block deals valued at approximately Rs 7,020 crore.

A floor price of Rs 5,808 per share, or about 4 per cent less than the closing price of the previous session, was anticipated for the block deal.

With this, the family’s persistent withdrawal from IndiGo continues.

They have been reducing their stake in the airline since Rakesh Gangwal left the board in February 2022; as of 2025, they have sold almost 9 per cent of the company.

(Also Read: What Is GST Compensation Cess? GST Council May End It By October 31)

By reducing their ownership of InterGlobe Aviation, Rakesh Gangwal and his family have raised more than Rs 45,300 crore since 2022.

In September 2022, a 2.74 per cent stake worth Rs 2,005 crore was sold. In February 2023, his wife, Shobha Gangwal, sold a 4 per cent stake for Rs 2,944 crore, and in August 2023, a further 2.9 per cent stake was sold for slightly more than Rs 2,800 crore.

Despite a 4.7 per cent increase in revenue, IndiGo recently reported a 20 per cent year-over-year drop in net profit for the first quarter of FY26, with earnings of Rs 2,176 crore.

Higher fuel prices, exchange rate fluctuations, and other external factors were the primary causes of the decline in profitability.

However, the airline continued to demonstrate strong operational performance, as evidenced by its 84.2 per cent passenger load factor and 87.1 per cent on-time performance.



Source link

Continue Reading

Business

Top stocks to buy today: Stock recommendations for August 28, 2025 – check list – The Times of India

Published

on

Top stocks to buy today: Stock recommendations for August 28, 2025 – check list – The Times of India


Top stocks to buy today (AI image)

Top stock market recommendations: According to Aakash K Hindocha, Deputy Vice President – WM Research, Nuvama Professional Clients Group, Nykaa, Kaynes, and Dr Reddy’s Laboratories are the top buy calls for today. Here’s his view on Nifty, Bank Nifty and the top stock picks for August 28, 2025:Index View: NiftyAfter an inside bar formation on Monday, Nifty opened with a gap down reeling all throughout the session ahead of its trading holiday on Wednesday. The index has closed below its trailing support of 24800 allowing for further downside to be opened for 24500 / 24350. Nifty has also formed a bearish head and shoulders formation on daily charts with a neck line support seen at 24450. A break below the same post monthly expiry could reel in further pressure on the index.Bank NiftyUnderperforming Nifty, Bank has broken its support of 55050 opening for a test of sub 54000 odd levels to begin with. The index has also closed at a 3.5 month low on daily charts ahead of its monthly expiry scheduled on Thursday. 55000 is likely to act as resistance on the upside while the index slides below sub 54000 levels in the coming week.NYKAA (BUY):

  • LCP: 231.65
  • Stop Loss: 223
  • Target: 252

Stock has been gaining traction ever since its 3 year triangle breakout seen in June 2025. For now NYKAA has given the highest ever close in past 3 years of trading along with a huge cup and handle breakout on daily and weekly charts. This opens up for a 18-20% trading buy target on the stock, yet we would advise for an initial uptick being 250+ on this leg.KAYNES (BUY):

  • LCP: 6197
  • Stop Loss: 5980
  • Target: 6620

After a cup and handle breakout in early August 2025, stock has been consolidating near the breakout zone for the past 4 weeks now. Last week’s price action suggests further move northwards from CMP as the stock has completed multiple retests of its ongoing breakout.Dr Reddy’s Laboratories (BUY):

  • LCP: 1263
  • Stop Loss: 1230
  • Target: 1355

Sustaining above its 200 DMA support, DRREDDY’s has also given a bullish flag breakout on daily charts. This allows its initial upside to open for the 1350-1360 zone where it could meet another potential breakout on upside.(Disclaimer: Recommendations and views on the stock market and other asset classes given by experts are their own. These opinions do not represent the views of The Times of India)





Source link

Continue Reading

Business

White House fires CDC director Monarez after she refuses to resign; 4 top health officials quit

Published

on

White House fires CDC director Monarez after she refuses to resign; 4 top health officials quit


Susan Monarez, President Donald Trump’s nominee to be the Director of the Centers for Disease Control and Prevention (CDC), testifies during her confirmation hearing before the Senate Committee on Health, Education, Labor, and Pensions in the Dirksen Senate Office Building on June 25, 2025 in Washington, DC.

Kayla Bartkowski | Getty Images

The White House on Wednesday said it had fired Centers for Disease Control and Prevention Director Susan Monarez after she refused to resign. Four other top CDC officials announced they were quitting the embattled health agency.

The leadership crisis at CDC erupted the same day the Food and Drug Administration announced new limits on who can get the latest approved round of Covid vaccines in the U.S.

“Susan Monarez is not aligned with the President’s agenda of Making America Healthy Again,” White House Spokesman Kush Desai said in a statement to NBC News. “Since Susan Monarez refused to resign despite informing [Health and Human Services Department] leadership of her intent to do so, the White House has terminated Monarez from her position with the CDC.”

The statement comes hours after attorney Mark Zaid said he was representing Monarez and that she had not actually been fired yet or stepped down, adding that she would not resign.

“When CDC Director Susan Monarez refused to rubber-stamp unscientific, reckless directives and fire dedicated health experts, she chose protecting the public over serving a political agenda,” Zaid said in a statement. “For that, she has been targeted.”

Earlier on Wednesday, HHS said in a post on X that “Monarez is no longer director” of the agency. 

Monarez, a longtime federal government scientist, was sworn in on July 31. She is the first CDC director to be confirmed by the Senate following a new law passed during the pandemic that required lawmakers to approve nominees for the role.

The Washington Post first reported her ousting on Wednesday. 

At least four other officials also submitted their resignations on Wednesday in a massive shakeup at the agency: Dr. Debra Houry, the CDC’s chief medical officer; Dr. Demetre Daskalakis, director of the National Center for Immunization and Respiratory Diseases; Dr. Daniel Jernigan, the director of the National Center for Emerging and Zoonotic Infectious Diseases; and Dr. Jennifer Layden, director of the Office of Public Health Data, Surveillance and Technology.

Houry, in a resignation letter obtained by NBC News, wrote about the dangers of the spread of vaccine misinformation and said proposed budget cuts and reorganization plans would negatively impact the CDC’s ability to address conditions like hypertension, diabetes, cancer, overdoses and mental health issues.

In his resignation letter, also obtained by NBC News, Daskalakis said he was leaving the agency “because of the ongoing weaponizing of public health.”

Her departure comes at a tumultuous time for the agency, which is reeling from a gunman’s attack on its Atlanta headquarters on Aug. 8. A police officer died in the shooting. 

Monarez on Friday canceled a meeting with CDC workers that had been scheduled for Monday, according to an email obtained by NBC News. She said she wanted to assure staff that the agency is working to restore their “trust in the safety and security of all CDC workplaces.”

President Donald Trump nominated Monarez after withdrawing his first pick to lead the CDC, former Republican congressman Dave Weldon, hours before his confirmation hearing. Weldon has been criticized for his views on vaccines

— CNBC’s Michele Luhn contributed to this report.



Source link

Continue Reading

Trending